<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Goldstein, J.</style></author><author><style face="normal" font="default" size="100%">Fuller, L.</style></author><author><style face="normal" font="default" size="100%">Delasalle, K.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Curability of solitary bone plasmacytoma</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">1992</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1992</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026582012&amp;partnerID=40&amp;md5=f47936d31ee15d13fa1853bd65cf1a7c</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">587 - 590</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: The effects of involved-field radiotherapy were assessed in patients with a solitary plasmacytoma of bone (SBP). Patients and Methods: Forty-five consecutive patients with an SBP received megavoltage irradiation of at least 3,000 cGy. The median age was 53 years, 67% of patients showed a myeloma protein, and uninvolved immunoglobulins (Igs) were preserved in 93% of patients. Results: Permanent control of presenting disease was achieved in all but two patients, but 46% of patients developed multiple myeloma. When it occurred, progression of myeloma occurred within 3 years in two thirds of the patients, suggesting that the extent of disease was understaged at diagnosis. Myeloma protein disappeared in nine patients (30%) whose disease has not yet recurred. The median survival for all patients was 13 years and the myeloma- specific survival fraction at 10 years was 53%. Conclusion: In patients with an SBP, the disappearance of myeloma protein with involved-field radiotherapy predicted long-term disease-free survival and possible cure. Nonsecretory disease and persistent myeloma protein after treatment were adverse prognostic factors for which adjuvant therapy with interferon alfa should be considered.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :80Export Date: 21 February 2017</style></notes></record></records></xml>